QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
$ 5.14 - $ 29.46
397,419
na
1.2B
$ 0.76
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Truist Securities analyst Danielle Brill initiates coverage on Upstream Bio (NASDAQ:UPB) with a Buy rating and announces Pri...

Core News & Articles

Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focu...

 upstreams-new-sinus-treatment-cuts-need-for-surgery-early-trial-finds

Upstream Bio's Phase 2 trial of verekitug in chronic rhinosinusitis met all endpoints, showing reduced nasal polyps, conges...

Core News & Articles

Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focu...

Core News & Articles

Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.49)...

Core News & Articles

Upstream Bio (NASDAQ:UPB) reported quarterly sales of $613.00 thousand which missed the analyst consensus estimate of $686.67 t...

 upstream-bio-is-new-on-nasdaq-can-potentially-beat-astrazenecas-asthma-drug-on-efficacy-analysts-say

Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION